Management Team

Our management team has a long track record of working successfully together in developing pharmaceuticals, biotechnology drugs and medical devices.

​Medivation’s executive team boasts experts from many facets of the healthcare industry, all of whom have a proven track record in medical product development. As seasoned business people and as clinicians and scientists, they guide Medivation in the acquisition and development of our technologies, bringing them from the laboratory bench to the patient bedside quickly, efficiently and with enhanced value.

David Hung, M.D.
David Hung, M.D.
President and Chief Executive Officer, Director
Dr. Hung served as president, chief executive officer and director of Medivation Neurology since its inception in September 2003. He became president and chief executive officer of Medivation, Inc. and a member of the Board of Directors when the Company acquired its subsidiary Medivation Neurology, Inc. in December 2004. From 1998 to 2001, Dr. Hung served as chief scientific officer (1998-1999) and as president, chief executive officer and director (1999-2001) of ProDuct Health, Inc., a privately-held medical device company focused on breast cancer cytological diagnostics. ProDuct Health, Inc was acquired in 2001 by Cytyc Corporation for $167 million after having spent only approximately $22 million in total development costs. From 1996 to 1998, Dr. Hung served in various senior positions at Chiron Corporation, most recently as vice president of lead discovery and development and vice president of new projects. Dr. Hung received an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine, and an A.B. summa cum laude in biology from Harvard College.

Rick Bierly
Rick Bierly
Chief Financial Officer
Rick Bierly was appointed chief financial officer in March 2014. Previously he served as an executive director in Ernst & Young’s (EY) Financial Accounting Advisory Services practice for life sciences and other clients. From 1999 to 2012, he served in several leadership roles at Johnson & Johnson, including vice president, Skillman NJ Shared Financial Services Center, where he was responsible for a shared services center providing financial accounting services to Johnson and Johnson’s US-based operating companies. He also served as vice president and chief financial officer of Centocor and Ortho Biotech, and prior to that served as executive director, finance, following the acquisition of the Centocor biotechnology business by Johnson and Johnson. From 1997 to 1999 he was at Centocor Diagnostics as vice president and chief financial officer and Centocor as executive director, finance. From 1995 to 1997 he served as vice president and treasurer of a Aventis-Hoechst start-up joint venture in the blood plasma business. He also worked in senior financial roles at Aventis (1991 to 1995) and SmithKline Beecham (1981 to 1991). He began his career in public accounting at EY. He holds a Bachelor of Business Administration degree from Pennsylvania State University and is a CPA in PA and NJ.

Cheryl L. Cohen
Cheryl L. Cohen
Chief Commercial Officer
Ms. Cohen was appointed chief commercial officer in September 2011. From 2008 to 2011, Ms. Cohen was president of CLC Consulting, a pharmaceutical and biotechnology consulting firm specializing in new product start-up and commercialization. She also served previously as the vice president, strategic commercial group, of Health Care Systems, Inc., a Johnson & Johnson company accountable for managed markets, contracting, and supply chain, where she was directly responsible for access of Johnson & Johnson products within one of the largest health plans in the country (2007 to 2008). From 1998 to 2007, she worked at Centocor, Inc., a Johnson & Johnson company, in a variety of senior sales roles including, vice president, rheumatology franchise, with direct responsibility for the $1+ billion per year Remicade® U.S. rheumatoid arthritis business and its 170-person sales and marketing team. Ms. Cohen began her career at Solvay Pharmaceuticals in a variety of sales positions (1992-1998). She earned her B.A. from Saint Joseph College.

Jennifer J. Rhodes
Jennifer J. Rhodes
General Counsel, Chief Compliance Officer and Corporate Secretary
Ms. Rhodes joined Medivation in June 2012 as our General Counsel, and was appointed Chief Compliance Officer in July 2012 and Corporate Secretary in April 2013. Between May 2006 and June 2012, Ms. Rhodes was an Assistant General Counsel at Pfizer Inc. where she supported the U.S. Primary Care Business and its Primary Care Medicines Development Group, and served as a legal product lead for Pfizer Inc.’s primary care medicines. Prior to joining Pfizer Inc., Ms. Rhodes was an associate in the regulatory law and international trade practice areas at Weil, Gotshal & Manges, LLP from October 2000 to April 2006. Between September 1998 and August 2000, Ms. Rhodes served as a law clerk for Chief Judge Gregory A. Carman on the United States Court of International Trade. Ms. Rhodes received a J.D. from Wake Forest University School of Law and a B.A. in Economics from Newcomb College of Tulane University.

Lynn Seely, M.D.
Lynn Seely, M.D.
Chief Medical Officer
Dr. Seely joined Medivation as chief medical officer in May 2005. From 2002 to 2005, she served as vice president of clinical development at Corgentech, Inc. (Anesiva, Inc.), a biomedical company. She served as vice president of clinical development at ProDuct Health, Inc., a privately-held medical device company, from 2000 to 2001, and subsequently served as vice president of clinical development for Cytyc Health Corporation, a medical device company and subsidiary of Cytyc Corporation, from 2001 to 2002. While there she assisted with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. From 1996 through 2000, she served as an associate director of clinical development at Chiron Corporation. Dr. Seely has led teams running clinical trials in all phases of development in a variety of therapeutic indications. Dr. Seely received an M.D. Alpha Omega Alpha from the University of Oklahoma, College of Medicine and completed her residency and served as chief resident in internal medicine at Yale-New Haven Hospital. She is board-certified in internal medicine and endocrinology and metabolism and was on the faculty at the University of California, San Diego prior to joining industry.

Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path.
Senior Vice President of New Projects
Dr. Kelsey joined Medivation in May 2013 as Senior Vice President of New Projects. Dr. Kelsey was previously at Geron Corporation as Executive Vice President, Head of Research & Development and Chief Medical Officer. He joined Geron in April 2009 as Executive Vice President and Chief Medical Officer, Oncology. From June 2002 until April 2009, Dr. Kelsey held various positions at Genentech, Inc., most recently as Vice President, clinical hematology/oncology. From June 2000 to June 2002, Dr. Kelsey was the Director of clinical affairs at Pharmacia Corporation (SUGEN, Inc.) and Director of global clinical development (oncology) at Pharmacia Corporation in Milan, Italy. From July 1993 to June 2000, Dr. Kelsey served as a Senior Lecturer in hematology/oncology at St. Bartholomews and the Royal London School of Medicine and Dentistry and visiting fellow at Vancouver General Hospital and Terry Fox Laboratories. Dr. Kelsey earned his B.Sc. in Pharmacology, M.B., Ch.B., and Doctorate of Medicine (M.D.) degrees from the University of Birmingham in the United Kingdom.

Top